project id: TCGA-PRAD; case submitter id: TCGA-EJ-A7NM; analyte type: DNA; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.97; rna integrity number: 9.4; age at index: 64; days to birth: -23603; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1949; age at diagnosis: 23603; ajcc clinical m: M0; ajcc clinical t: T3b; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 128.0; icd 10 code: C61; last known disease status: not reported; morphology: 8500/3; primary diagnosis: Infiltrating duct carcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 115; initial weight: 410.0; sample id: 1f3baf15-bca3-4f5a-b3d8-128bf05882f8; sample submitter id: TCGA-EJ-A7NM-01A; portion id: d9ece443-9c66-4393-9c2d-17b372581133; portion submitter id: TCGA-EJ-A7NM-01A-21; slide id: a67844dc-708c-45e2-af9f-cb619d24515e; slide submitter id: TCGA-EJ-A7NM-01A-02-TSB; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0; section location: TOP;